MOUNTAIN VIEW, Calif.,
June 30, 2014 /PRNewswire/ -- Alexza
Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced the promotion
of Edwin S. Kamemoto, Ph.D., to the
newly created position of Senior Vice President, Regulatory
Affairs. Dr. Kamemoto will have primary responsibility for
leading and directing all regulatory affairs and global
pharmacovigilence activities.
Dr. Kamemoto has been Alexza's Vice President, Regulatory
Affairs since July 2012. He joined Alexza in 2006 as
Associate Director, Regulatory Affairs, was promoted to Director,
Regulatory Affairs in 2007, to Senior Director, Regulatory Affairs
in 2008, and to Executive Director, Regulatory Affairs in
2010. From 2004 - 2006, Dr. Kamemoto was a consultant for
CATO Research, a contract research organization. From 1995 to
2004, he held various scientific and regulatory affairs managerial
positions at Nektar Therapeutics, a publicly traded
biopharmaceutical company. He held previous scientific-related
positions at Glycomed, Inc. and Celtrix Pharmaceuticals, Inc., both
publicly traded biopharmaceutical companies. Dr. Kamemoto received
a Ph.D. in biochemistry from UCLA,
completed a postdoctoral fellowship at Stanford University and received a B.S. in
chemistry and biology from University of Hawaii.
About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development and
commercialization of novel, proprietary products for the acute
treatment of central nervous system conditions. Alexza's products
are based on the Staccato® system, a hand-held inhaler
designed to deliver a drug aerosol to the deep lung, providing
rapid systemic delivery and therapeutic onset, in a simple,
non-invasive manner.
ADASUVE® is Alexza's first commercial product and it
has been approved for sale by the U.S. Food and Drug Administration
and the European Commission. Teva Pharmaceuticals USA, Inc. is Alexza's commercial partner for
ADASUVE in the U.S. Grupo Ferrer Internacional S.A. is
Alexza's commercial partner for ADASUVE in Europe, Latin
America and the Commonwealth of Independent States
countries.
ADASUVE® and Staccato® are registered
trademarks of Alexza Pharmaceuticals, Inc.
SOURCE Alexza Pharmaceuticals, Inc.